Suppr超能文献

[西班牙肝性脑病的诊断与治疗:肝病专家调查结果]

[Diagnosis and treatment of hepatic encephalopathy in Spain: results of a survey of hepatologists].

作者信息

Vergara-Gómez M, Flavià-Olivella M, Gil-Prades M, Dalmau-Obrador B, Córdoba-Cardona J

机构信息

Unitat de Malalties Digestives, Corporació Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.

出版信息

Gastroenterol Hepatol. 2006 Jan;29(1):1-6. doi: 10.1157/13083245.

Abstract

INTRODUCTION

Hepatic encephalopathy is a common complication of cirrhosis. Recent studies have challenged the efficacy of nonabsorbable disaccharides and have reported that protein restriction may pose risks to patients with cirrhosis and hepatic encephalopathy.

AIM

To determine the diagnostic and therapeutic practices of physicians treating patients with hepatic encephalopathy.

MATERIAL AND METHODS

We designed a 20-item questionnaire, which was mailed to the members of the Spanish Society for the Study of the Liver.

RESULTS

We received 128 questionnaires, completed by physicians with wide clinical experience. They reported that the most common precipitating factors in episodic encephalopathy were infections (22%), diuretics (21%), and gastrointestinal bleeding (21%). The usual treatment of episodic encephalopathy was administration of nonabsorbable disaccharides (90%) and protein restriction (52%). Patients with chronic encephalopathy were also usually treated with nonabsorbable disaccharides (94%) and protein restriction (40%). Fifty-nine percent of the hepatologists never carried out neurophysiologic or neuropsychologic assessment for the diagnosis of minimal hepatic encephalopathy.

CONCLUSION

Although their efficacy has been questioned, nonabsorbable disaccharides and protein restriction are the most commonly prescribed treatments for hepatic encephalopathy. Future studies are needed to assess the efficacy and risks of these treatments. Most hepatologists never assess minimal hepatic encephalopathy in patients with cirrhosis.

摘要

引言

肝性脑病是肝硬化的常见并发症。最近的研究对不可吸收双糖的疗效提出了质疑,并报告说蛋白质限制可能给肝硬化和肝性脑病患者带来风险。

目的

确定治疗肝性脑病患者的医生的诊断和治疗方法。

材料与方法

我们设计了一份包含20个条目的问卷,并将其邮寄给西班牙肝脏研究学会的成员。

结果

我们收到了128份问卷,由具有广泛临床经验的医生填写。他们报告说,发作性脑病最常见的诱发因素是感染(22%)、利尿剂(21%)和胃肠道出血(21%)。发作性脑病的常用治疗方法是给予不可吸收双糖(90%)和蛋白质限制(52%)。慢性脑病患者通常也接受不可吸收双糖(94%)和蛋白质限制(40%)治疗。59%的肝病专家从未进行过神经生理学或神经心理学评估以诊断轻微肝性脑病。

结论

尽管不可吸收双糖和蛋白质限制的疗效受到质疑,但它们仍是肝性脑病最常用的处方治疗方法。需要进一步研究来评估这些治疗方法的疗效和风险。大多数肝病专家从未对肝硬化患者的轻微肝性脑病进行评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验